Investigating Key Non-coding RNAs and Their Interaction with Chromatin Remodeling in Breast Cancer Patients for Diagnosis and Prognosis

What this Trial Is About

Breast cancer is a common and deadly disease in women worldwide, characterized by several subtypes based on hormone receptor status. Researchers are investigating the role of epigenetic regulators, such as non-coding RNAs (ncRNAs) including long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), and chromatin remodeling proteins in breast cancer development and progression. This study focuses on two specific lncRNAs, UPK1A-AS1 and UNC5B-AS1, which have not yet been studied in breast cancer patients, aiming to understand their diagnostic and prognostic potential as well as their interaction with chromatin modifying proteins and target miRNAs. The study will measure the expression levels of lncRNAs UPK1A-AS1 and UNC5B-AS1 and their target miRNAs in serum (liquid biopsy) and/or tissue samples from breast cancer patients using quantitative real-time PCR (qRT-PCR). Additionally, protein levels related to these ncRNAs will be quantified in serum and/or tissue samples by ELISA. The study will compare these molecular markers with classical tumor protein markers and correlate the findings with clinical and pathological characteristics of breast cancer, such as tumor stage, grade, receptor status, and other prognostic biomarkers. Participants will provide blood and tissue samples for analysis, and clinical data will be collected from medical records. Laboratory tests include RNA extraction, qRT-PCR, and ELISA for protein measurement. Researchers will analyze the relationships between ncRNA and protein expression and clinical features over about 12 months. The study also includes statistical analysis to assess the significance of findings, with the goal of identifying new markers that could improve breast cancer diagnosis and prognosis, and potentially serve as targets for gene therapy.

"Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients"